Stockscreener 앱 받기
67.81
0.78%
0.535
전일 마감가:
$67.28
열려 있는:
$66.42
하루 거래량:
1.13M
Relative Volume:
0.09
시가총액:
$138.48B
수익:
$48.48B
순이익/손실:
$7.27B
주가수익비율:
19.04
EPS:
3.5626
순현금흐름:
$11.91B
1주 성능:
+2.66%
1개월 성능:
+9.21%
6개월 성능:
+10.62%
1년 성능:
+43.87%
1일 변동 폭
$66.42
$67.88
1주일 범위
$65.13
$68.64
52주 변동 폭
$42.52
$68.64
브리스톨 마이어스 스퀴브 Stock (BMY) Company Profile
명칭
Bristol Myers Squibb Co
전화
(609) 252-4621
주소
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, MRK, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
67.79 | 133.74B | 48.48B | 7.27B | 11.91B | 3.5626 |
LLY
Lilly Eli Co
|
1,262.23 | 1.11T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
273.56 | 644.33B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
266.24 | 462.68B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
154.52 | 367.58B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
159.97 | 296.97B | 54.66B | 13.58B | 16.05B | 7.0171 |
브리스톨 마이어스 스퀴브 Stock (BMY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-25 | 개시 | RBC Capital Mkts | Sector Perform |
| 2026-02-20 | 개시 | Barclays | Overweight |
| 2026-01-07 | 업그레이드 | UBS | Neutral → Buy |
| 2025-12-15 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-12-12 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Perform |
| 2025-08-05 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2025-04-22 | 개시 | Piper Sandler | Overweight |
| 2024-12-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-13 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-07-29 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-03-11 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2024-02-06 | 다운그레이드 | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-11-15 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-02 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2023-10-27 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-07-14 | 개시 | HSBC Securities | Reduce |
| 2023-07-10 | 개시 | SVB Securities | Market Perform |
| 2023-06-28 | 개시 | Daiwa Securities | Outperform |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-01-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-11-18 | 개시 | Credit Suisse | Neutral |
| 2022-10-10 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-09-14 | 다운그레이드 | Berenberg | Buy → Hold |
| 2022-06-03 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | 재개 | Morgan Stanley | Underweight |
| 2021-12-17 | 개시 | Goldman | Buy |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-11-01 | 다운그레이드 | Argus | Buy → Hold |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-04-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | 업그레이드 | Truist | Hold → Buy |
| 2020-11-16 | 업그레이드 | Societe Generale | Hold → Buy |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-11-06 | 다운그레이드 | Gabelli & Co | Buy → Hold |
| 2020-10-19 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-09-29 | 개시 | Berenberg | Buy |
| 2020-07-28 | 개시 | Raymond James | Outperform |
| 2020-04-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-01-06 | 재개 | Citigroup | Buy |
| 2019-12-13 | 업그레이드 | Argus | Hold → Buy |
| 2019-11-22 | 재개 | Morgan Stanley | Equal-Weight |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-08-14 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | 개시 | Goldman | Buy |
| 2019-05-20 | 다운그레이드 | Argus | Buy → Hold |
| 2019-05-03 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-05-03 | 재개 | JP Morgan | Overweight |
| 2019-01-15 | 업그레이드 | Societe Generale | Sell → Buy |
| 2018-10-22 | 다운그레이드 | Citigroup | Buy → Neutral |
모두보기
브리스톨 마이어스 스퀴브 주식(BMY)의 최신 뉴스
Bristol-Myers Squibb (BMY) Bets $2.3 Billion on Texas While Eli Lilly (LLY) Wins in the UK - Yahoo Finance
Why Bristol Myers Squibb (BMY) Stock Is Up Today - Quiver Quantitative
Bristol-Myers Squibb Co Stock (BMY) Moved Up by 3.06% on Aug 21: Drivers Behind the Movement - TradingKey
BMY|Bristol-Myers Squibb Co|Price:67.010|Chg%:+1.540 - TradingKey
Can Eliquis Cushion Bristol Myers' Legacy Portfolio Erosion? - Yahoo Finance
Roundup: Amplitude Therapeutics, Chai Discovery Enter Collaborations with Eli Lilly, Bristol Myers Squibb - Pharmaceutical Executive
Chai partners with Bristol Myers Squibb on AI-driven antibody discovery - The Pharma Letter
Paralel Advisors LLC Acquires Shares of 38,091 Bristol Myers Squibb Company $BMY - MarketBeat
104,121 Shares in Bristol Myers Squibb Company $BMY Bought by TrinityBridge Ltd - MarketBeat
OneAscent Financial Services LLC Takes Position in Bristol Myers Squibb Company $BMY - MarketBeat
LaSalle St. Investment Advisors LLC Takes $1.12 Million Position in Bristol Myers Squibb Company $BMY - MarketBeat
Tocqueville Asset Management L.P. Invests $5.30 Million in Bristol Myers Squibb Company $BMY - MarketBeat
Vise Technologies Inc. Acquires Shares of 141,913 Bristol Myers Squibb Company $BMY - MarketBeat
Bank of New York Mellon Corp Decreases Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Allworth Financial LP Makes New Investment in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb stock edges higher as AI antibody deal and Q2 earnings support outlook - Ad-hoc-news.de
Hillman Value Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol-Myers Squibb Co (BMY) Shares Fall 3.2% -- GF Value Says Still Overvalued - GuruFocus
Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors - MarketWatch
Bristol-Myers Squibb Co Stock (BMY) Closed Down by 3.17% on Aug 20: Facts Behind the Movement - TradingKey
UBS reiterates Buy on Bristol-Myers Squibb stock, $80 target - Investing.com
Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO - AOL.com
Chai tees up Bristol Myers Squibb AI antibody discovery collab - Fierce Biotech
UBS reiterates Buy on Bristol-Myers Squibb stock, $80 target By Investing.com - Investing.com Canada
Bristol Myers Squibb stock steadies as FDA approval and Houston expansion reshape outlook - Ad-hoc-news.de
Bristol-Myers Squibb partners with Chai Discovery to leverage AI in developing new therapies - 富途牛牛
Bristol Myers Squibb, Chai Partner on AI Antibody Discovery - Contract Pharma
Chai Discovery Announces Collaboration with Bristol Myers Squibb to Advance AI-Driven Antibody Discovery - Business Wire
United Bank Acquires New Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Johnson Financial Group Inc. Buys Shares of 21,307 Bristol Myers Squibb Company $BMY - MarketBeat
33,580 Shares in Bristol Myers Squibb Company $BMY Acquired by one8zero8 LLC - MarketBeat
Patrick Mauro Investment Advisor INC. Acquires New Position in Bristol Myers Squibb Company $BMY - MarketBeat
Knuff & Co LLC Acquires New Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Edmond DE Rothschild Holding S.A. Acquires Shares of 113,537 Bristol Myers Squibb Company $BMY - MarketBeat
Bell & Brown Wealth Advisors LLC Invests $2.46 Million in Bristol Myers Squibb Company $BMY - MarketBeat
Abacus FCF Advisors LLC Makes New $13.11 Million Investment in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
Stock Traders Buy High Volume of Bristol Myers Squibb Call Options (NYSE:BMY) - MarketBeat
Bristol Myers Squibb (NYSE:BMY) Sets New 52-Week HighWhat's Next? - MarketBeat
Bristol-Myers Squibb stock hits 52-week high at 68.1 USD - Investing.com
AstraZeneca Vs. Bristol-Myers Squibb: Who’s The Better Bargain For Investors (NYSE:BMY) - Seeking Alpha
FESTIVAL ANNOUNCEMENT: 32nd Annual One Mind Music Festival Presented by Bank of America and Bristol Myers Squibb - 巴士的報
FESTIVAL ANNOUNCEMENT: 32nd Annual One Mind Music Festival Presented by Bank of America and Bristol Myers Squibb – Company AnnouncementFT.com - Financial Times
Hematogenix's MM MRD Assay Underpins FDA Accelerated Approval of Bristol Myers Squibb's ZENBEXUS™, the First Approved CELMoD Therapy for Multiple Myeloma - Yahoo Finance
Why Novartis, Lilly, and Bristol Myers Are Eyeing This Clinical-Stage Cancer Play - AOL.com
Bristol Myers Squibb to build $2.3B manufacturing campus in Houston - Yahoo Finance
Bristol-Myers Squibb stock holds gains as Zenbexus approval and fresh guidance shape the outlook - AD HOC NEWS
Bristol Myers Squibb Company $BMY Holdings Trimmed by Pzena Investment Management LLC - MarketBeat
Great Lakes Advisors LLC Makes New Investment in Bristol Myers Squibb Company $BMY - MarketBeat
Danica Pension Livsforsikringsaktieselskab Buys New Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Diversify Advisory Services LLC Invests $2.33 Million in Bristol Myers Squibb Company $BMY - MarketBeat
브리스톨 마이어스 스퀴브 (BMY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.68%
자본화:
|
볼륨(24시간):